Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Interline Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, NEAGU, IRINA, in 1 distinct art unit. NEAGU, IRINA is the busiest examiner with 1 pending office action. The company's current prosecution profile is defined by this single pending matter in the biotechnology field.
The 1 pending office action is the only case currently being prosecuted by the company at the USPTO. This means that NEAGU, IRINA has total influence over the company's current patent applications. Practitioners should tailor their approach to the specific requirements of the 1 distinct art unit and the examiner's past rulings. Since there are no other pending office actions, the company's resources can be fully committed to this one matter. The resolution of this 1 pending office action is critical for the company's intellectual property position in the Biotechnology & Pharmaceuticals technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.8% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18942025 | LRRK2 INHIBITORS | NEAGU, IRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18942025 | LRRK2 INHIBITORS | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18942025 | LRRK2 INHIBITORS | NEAGU, IRINA | 1629 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInterline Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Irina Neagu has the most, with 1 of Interline Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.